Mr. Anurag Tantia
executive director at GPT Healthcare Limited
Replay available
GPT Healthcare (NSE:GPTHEALTH) Q2 2027 earnings call, held 2026-11-06. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/gpt-healthcare-limited-gpthealth-q2-2027-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Ladies and gentlemen, good day, and welcome to the GPT Healthcare Limited Q2 and H1 FY 'twenty seven Earnings Conference Call. As a reminder, all participant lines will be in the listen only mode, and there will be an opportunity for you to ask questions after the presentation concludes. To discuss this quarter's performance, we have from the management, Mr. Anurag Tantia, executive director. Before we proceed with this call, I would like to mention that some of the statements made in today's call may be forward looking in nature and may involve risks and uncertainties. For more details, kindly refer to the investor presentation and other filings that can be found in the company's website and stock exchanges.
0:47 With that, I would like to hand over the call to Mr. Anurag Tantia for his opening remarks. Thank you, and over to you. Good morning, everyone, and thank you for joining us today for GPT Healthcare Limited's Q2 and H1 FY 'twenty seven earnings conference call. I would like to take this opportunity to wish you and your families a very Shubh Deepavali. To begin with, let me briefly touch upon the key trends shaping the Indian healthcare sector and the structural growth drivers that continue to underpin our long term strategy. The Indian healthcare sector continues to witness strong structural growth, supported by rising health awareness, increasing prevalence of lifestyle related and chronic diseases, higher health insurance penetration and growing demand for specialized medical services.
1:33 The demand for quality healthcare is also being driven by an aging population, advancements in medical technology and increasing affordability of advanced treatments. Despite this growth, India continues to have a significant gap in healthcare infrastructure, particularly in hospital bed availability and access to quality tertiary and specialized care. This creates a meaningful opportunity for organized hospital chains to expand their presence, especially across tier two cities. At the same time, the increasing complexity of medical requirements is making technology and specialized clinical capabilities important differentiators for hospital operators. Investments in advanced medical equipment, robotic assisted procedures and specialized treatment infrastructure enables hospitals to broaden their clinical offerings, address complex medical needs and enhance their ability to attract patients.
2:26 At GPT Healthcare, we are focused on strengthening these capabilities across all our hospitals in the network. We have introduced robotic assisted surgery at ILS Solid Lake and ILS Hubra alongside investments in advanced oncology and diagnostic infrastructure. These initiatives are aimed at expanding our service capability offerings, improving access to advanced treatment options and further strengthening our clinical capabilities. Let me now take you through our operational and financial performance for Q2 and H1 FY twenty twenty seven. We have continued to build on momentum across our hospital network, delivering healthy growth through improved patient volumes, better utilization of our established facilities and a stronger contribution from specialized clinical services.
3:11 During Q2 FY twenty twenty seven, revenue from operations stood at INR135.6 crores registering a growth of 14.1% year on year. This growth was driven by improved occupancy levels, higher patient throughput and favorable case mix across our network hospitals. EBITDA grew at a faster pace increasing by 23.9% year on year to INR29.8 crores. The EBITDA margin expanded by 150 basis points to 21.5% compared with 20% in the corresponding quarter last year. Profit after tax increased by 45.2% to INR15.4 crores with PAT margin expanding by two thirty basis points to 11.1%, reflecting the strong flow through of operational growth to the bottom line.
3:58 On the operational front, RCOP for the quarter stood at Rs. 40,721 reflecting year on year growth of 7.1%. The network occupancy improved to 50.3% compared with 47.4% in the corresponding quarter last year. Excluding the RIPOR, occupancy across our mature hospitals stood at 59.8%, indicating improved utilization across our established network. Turning to our H1 twenty seventeen performance. Revenue from operations grew by 15.8% year on year to INR261.8 crores demonstrating sustained business momentum across the network. EBITDA increased by 30.3% to INR56 crores with margins improving by two twenty one basis points to 21% compared with 18.8% in H1 FY 'twenty six.
4:46 Profit after tax increased by 53.9% to INR28.1 crores with a PAT margin of 10.5% with an average margin expansion of two fifty six basis points. Our H1 ARPU stood at forty one thousand four ninety, while network occupancy was 47.9% compared with 44.7% in H1 FY 'twenty six. Occupancy across mature hospitals stood at 56.7% excluding Redwood. Our overall performance was supported by steady progress across the hospital network with contributions from both established and newer facilities. Among our established hospitals, ILSOLDLE continued to deliver a strong performance recording an occupancy of 65.4% in H1 and the highest ARPA across our network at 43,284.
5:36 The hospital also registered year on year growth of 12% and crossed the milestone of eight fifty robotic surgeries, reflecting its growing expertise in advanced and technology enabled clinical procedures. Moving to ILS Dum Dum. The hospital continued to deliver a robust operating performance and remained the largest revenue contributor to our network. During H1 FY 'twenty seven, it recorded revenue of INR84.8 crores with occupancy of 69.4% and an RRP of INR4386. Further strengthening its clinical capabilities, the hospital has commenced a cardiothoracic and vascular surgery unit aimed at providing comprehensive cardiac care under one roof and expanding access to advanced cardiac treatments. At ILS Agartala, the hospital continues to strengthen its position as a leading center for specialized oncos care in Tupurah. Its oncology program has gained significant traction with over 3,200 radiation therapy procedures performed through its Tynak facility and more than 1,000 PET scans completed in just over a year.
6:39 The hospital recorded year on year growth of 8.1% in FY twenty twenty seven with an ARPPUB of INR40254, reflecting steady operational performance. ILS Havre, the hospital is witnessing encouraging growth with revenue increasing by 25% year on year basis in H1 FY twenty seven, supported by higher patient volumes and improved occupancy of 45.8%. The hospital has also strengthened its orthopedic capabilities with the launch of the Mako robotic knee surgery system and is nearing the milestone of 100 robotic procedures. Moving to our U. S. Facility, ILS Raipur, which marks our first entry into Central India. We are encouraged by the progress it has made during its initial phase of operations. It achieved NABH accreditation within its first year of operations, performing its first TAVI procedure and liver transplant in Q2 FY twenty twenty seven. It has also completed 11 renal transplants in just under the year.
7:37 Looking ahead, we remain committed to achieving ROE and ROCE of approximately 25% supported by disciplined capital allocation, prudent leverage and a focus on improving returns from our existing assets. Jamshethu project is progressing as planned with the upcoming 155 bed tertiary care hospital expected to commence operations in March April twenty twenty seven. This expansion will further strengthen our presence across Eastern India and enhance access to quality healthcare in the region. To conclude, we believe GPT Healthcare is well positioned to capitalize on the long term growth opportunities in Indian healthcare sector, particularly across the underserved markets of Eastern And Central India. Our established hospital network, diversified clinical capabilities, strong doctor relationships and proven track record of achieving hospital level breakeven provide a strong foundation for sustainable growth.
8:29 With that, I conclude my opening remarks, and I request the moderator to open the floor for questions. Thank you. Thank you very much. We will now begin the question and answer session. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. We'll take our first question from the line of Richard Chaudhry from Electrum PMS. Please go ahead. Yes. Hi, sir. Thank you for the opportunity. So I just wanted to understand this quarter across all your hospitals, we saw increase in utilization.
9:16 But at the same time, when we see and, we saw drop in the ARPOP sequentially. So any specific reason for the same? And second question is right for utilization if we see it hasn't picked up quarter on quarter. And if you could just tell us what were the losses for this quarter that we saw? Sure. So RPUB drop is a very minor amount in the overall network, and that is primarily on account of seasonal variations. Quarter two tends to have a high fever season, which results in a slight change in specialty mix. In terms of Raipur, we have seen encouraging growth in that hospital. There has been some amount of slightly lesser productivity on account of seasonal change and some attrition on account of increased competition. But we've been able to fill those gaps and are hopeful for better performance in the ensuing quarters.
10:13 Okay. And what are the losses for this quarter in Raipur? The Raipur losses for this quarter have been to the tune of around 9 crores, which overall in H2 have been to the tune of around INR 9 crores, which is in line with the expectation. H1 losses were at INR 9 crores or it was... Sorry, H1 losses were at INR 6.5 crores, which are in line with our expectation. Okay. And when are we expecting this to breakeven probably by next year or quarter two or like that? Could you just give us that Generally, new tertiary care hospitals end up taking almost three years to breakeven on a monthly basis. We expect this hospital to breakeven by Q1 of next year on a monthly basis. Okay. And is there any update on the acquisition of greenfield CapEx for the upcoming hospital after them?
11:09 Are constantly evaluating opportunities. There are opportunities which come in. It is about finding the suitable and the appropriate mix. We do not intend to enter into an agreement just for the sake of expansion. They have to be meaningful contributors to the overall bottom line and top line. So we are looking for suitable opportunities and once once they they tick, are we'll definitely let you know. Thank you so much. Okay. Thank you. Thank you. Next question is from the line of Aditya Chedha from Incred Asset Management. Please go ahead. Hi, good morning. Good morning. So can you update on the regulatory landscape for kidney transplant and whether the deemphasis of nephrology is completed at Dum Dum?
11:56 So we have there is no change in the landscape with regards to the renal transplant program. With regards to the nephrology program in Dhamdan, we have been working on reducing our dependence on the same and we've significantly been able to reduce the contribution of the overall nephrology department in the overall scheme of things. The contribution of the department is now less than around 15% compared to it being almost 30% earlier. Right. Can you talk about, you know, in comparing Q2 Y o Y, Adelta line, how would I have both seen almost double digit ARPU growth? So what is driving this for us? These have been driven by increased productivity numbers and obviously a change in specialty mix. We have been focused on higher end specialties. These combined with improved productivity numbers are driving the growth.
12:55 Right. And if you want to share your outlook on how do you see FY 'twenty seven paying out? And any comments on the likely lease expenses that you would see from Raipur and Jamshedpur both on an absolute basis, if you can quantify those, that will be it. That those are my questions. So we are committed to our initial estimates of FY 'twenty seven numbers. We are on track to achieving around 15% to 16% growth over last year. In terms of the lease expenses of Raipur and Jamshedpur, Raipur is already operational with the lease expense of almost 4 crores a year. Jamshedpur would also be a similar amount. Next question is from the line of Avinesh Balasubramaniam from Brookfield Estate. Please go ahead.
13:55 Good morning, sir. Thank you for taking my question. In the earlier calls, basically, just want to understand how the management is thinking about growth. Because in the earlier conference, had data that the legacy hospitals will reach occupancy of 70% in the next twelve months or eighteen months, right? So when that happens, I think the company can generate an EBITDA of anywhere in the back of INR130 crores to INR150 crores. So the company does have the right result of probably invest around INR100 crores each year for expansion. So I just wanted to understand how the management is thinking about that. Is there an internal guideline that the management wants to add a certain number of beds going forward? Just wanted to kind of understand your thoughts on that. Sure.
14:41 So the management is intent upon growth, and we are looking at adding hospitals every couple of years to our overall portfolio. We are commissioning a jump ship for hospital in March or April of calendar twenty twenty seven. That will add another 155 beds to our overall network. Apart from this, we have been actively scouting for opportunities in the Eastern part of the country, both greenfield and acquisition opportunities. It is about the right one clicking for us. It is something which the management is intent on doing and is continually evaluating them. In this point, maybe I have a suggestion. If the company can look at acquiring some land in three, four places and then kind of sequentially commissioning the hospitals. Sure. Thank you for your suggestion. That is something which is already under action.
15:31 Hopefully, we'll be getting to know of its own. Thank you so much. Thank you, sir. Thank you. Next question is from the line of Anubhav Mukherjee from Crescent Capital. Please go ahead. Am I audible? Yes, please go ahead. Congrats on strong results. I have a few basic questions as I'm like looking at the company like recently. So my first question is that the Agartala Hospital, like it is the second oldest hospital in our network. But its occupancy is still like around 54%. So and in fact, come lower compared to maybe like Dum Dum, which was started two years later.
16:18 So can you share some historical perspective on like why is the utilization like comparatively lower and... Yeah. So Agathala, the hospital Agathala is located in Tripura, which is a Northeastern state. Operating in the Northeast, especially in a state like Tripura, which is far away from the mainland comes with its own operational challenges. We have faced significant challenges in the past with regards to recruitment of clinicians, which we have overcome with due time as the hospital reputation has increased. This is a constant process where we are adding consultants to this hospital. It is a challenging environment to get consultants, but we've been fairly successful at it, which reflects on the growth the hospital has been able to do in the past few years.
17:04 We are hopeful with the increasing momentum from these new consultants who've been added, we will be able to get to an optimal occupancy soon. Yes, that can be in line with other older hospitals, we believe that even Agartala can go up to like 70%, 75% occupancy? We are very hopeful with the momentum we have. We should be able to reach the optimal occupancy of 70% very soon. Yes. Thanks for that perspective. And at our existing hospitals, full mature hospitals, is there any scope for any brownfield bed addition? In the Calcutta hospitals, there is no further scope for brownfield bed addition. We have scope to add beds in Odetsala and in Draper.
17:51 Okay. And we'll look at that in, like, one We will activate those when the hospital once the hospital reaches an optimal occupancy where growth can be sustained. Okay. And another like maybe slightly dumb question, like is the, like, therapy mix quite different across our three hospitals in Calcutta? Because Aurora seems to have a lower ARPU compared to the Dhamsat and Salt Lake Hospital. So, can you share the reason for this? Sure. So, Dhamdan being obviously a coronary care hospital where there is a significant amount of revenue from tertiary care specialties like cardiology and nephrology, etcetera, does tend to have a higher RPUB.
18:39 The product mix however is slightly different on account of its location, but it is also something which is developing with time. We've been constantly adding new departments to the hospital as well. We expect the ARPAB to come up to the unknown standards, but at the same time, we also need to keep in mind the payer profile and the location of that unit where the ARPAB might always be muted compared to something in Mainland Canada. Just a final small question. We were looking at hospital addition in Rachi also, I suppose, in the recent past. So is that like brand dropped off or like, yes? So Doraci MOU which was signed could not be executed because the owner it was an asset light hospital where the owner landed to some went into some legal troubles. So we could not complete that project. However, we deviated and we are on the verge of commissioning our Jamshed Hospital, which is also in Jharkhand.
19:49 Next question is from the line of Maisar Shah from AMPL Asset Management. So just on Lightwood, I thought earlier you were guiding for breakeven in Q3, and now you are saying breakeven in Q1 FY 'twenty eight. Is that correct? Yes. There is a reason for it, which I touched upon earlier as well. There was some amount of attrition in our clinical talent on account of newer entrants which had entered the market. But we've been able to bridge that gap, we've been able to get all consultants back in again. That has delayed the breakeven timeline slightly, but that is something which is well in our control and we are back on track for that. Maybe any guidance you can give on exit utilization by Q4? Sorry? Exit occupancy rate by Q4 at 27%, any guidance on occupancy?
20:46 We expect the average occupancy to be around the 25% to 30% mark by the end of Q4. Okay. And you said you can add beds at Agartala or is there one more hospital you said that you can add beds, ground feet or it's only at Agartala? We have expansion capability within our existing premises at Agartala. And at Raipur Hospital, we have the capability to take up additional space from the developer and add beds. Okay. So Agartala and Raipur, when the need arises, how many beds you can add, downfield? Both the hospitals, we can add another 100 beds. Put together? Yeah. No. Each of them.
21:31 Okay. Each. Okay. And, Anurag, I was just wondering, at Raipur, you got insurance impairments from most of the insurance or that is still in work in progress? It is still a work in progress. We've been able to have the impairment of almost seventy percent of the players. There are still some insurance providers who are not on board. We are working very closely with them to come to an agreement soon. Okay. And also I was just wondering, I know at Raipur you said initially to pay more rates, you had said that you would look at adding more government patients, right? So is that strategy on track? We have been taking Aishman Bharat patients there, but obviously we have to do it keeping in mind the overall cash flow position.
22:18 So we have been taking some Aishman Bharat patients along with that. We've also started corporate patients from SAIL, from Coal India, etcetera, and other major corporates in that region as well. So in corporate ARPU, how does it compare with Ayushman ARPU in terms of cash collection? Corporate ARPUs generally work at three digit rates, which are slightly better than Aishman rates. And how about cash collection? Payment cycle generally is within ninety days. Within ninety days? Yes. Okay. And, you know, since our occupancy in couple of hospitals is very low, I know we are more focused on cash and insurance where, you know, those patients are 90% plus of revenues.
23:08 But our occupancies are very low. I've seen so many hospitals where they restrict government or corporate to sell less than 20%, 25%. So would it not be a wise strategy? I know you know it. I know you know this better, but to maybe take some more patients, Harishman, or Corrid, so that you can fill your beds faster. And obviously, you limit within certain numbers, whatever that you internally decide. I understand it will to higher data, but it will help you on overall operating leverage and the utilization. Sure. Thank you for your suggestion. We do do that in the hospitals where we feel we can control the receivables and at the same time increase occupancy. We are doing that in the rental and in Dreyfur where the requirement is there. So you said you are doing only Agartala? We have been doing it extensively in Agartala and in Raipur. In Calcutta also, have been taking some patients, but not a whole lot because we don't have spare beds available. But in Agartala and Raipur, we have been taking Aishman Bharat patients.
24:04 This is obviously the receivables and the specialty mix. So in Adhatala, despite you taking government and corporate, your occupancy is still very low. But how are there also the occupancy is low, right? So there you cannot take government and corporate have to be we have to be mindful of the specialty mix and the receivable cycle when we are taking these patients, and we do it basis optimal utilization of both. Okay. Okay. Thank you very much and all the best. Thank you. Thank you. Next question is from the line of Dixit Doshi from Whitestone Financial Advisors. Please go ahead. Yes. Thanks for the opportunity. Most of my questions are answered. Just one question is after the recent Supreme Court judgment on trade margins on essential medicine, can that impact anyway to our margins?
25:03 That is something which will be we'll have more clarity once the order comes out and once the effect comes out in November second week. But that is health care has to be seen at an overall basis. These were just components in the overall service pricing. Obviously, service pricing basis that has to be corrected so that the margins are maintained and that is what our intention will also be. Fine. Thank you. You. Next question is from the line of Anubhav Mukherjee from Crescent Capital. Please go ahead. Thanks for the follow-up opportunity. I have another basic question. Like, most of the hospitals in your network and also the additions that you're doing seem to be mid sized hospital, like, 200 beds.
25:54 Some of the other listed, like especially the larger teams, they look at like setting up like larger hospitals, 400,500 beds in one place. So like can you share your thought process on this? Is this like a reflection of the geography you are operating in or your business model of like more leased hospitals? So can you share your thought process on this? Sure. So it is not a product of more leased hospitals. It is more a product of, a, as you correctly said, the geography b, these are optimally designed hospitals, which give us better control in terms of our costs, it leads to a faster breakeven for us also. Generally, our hospitals breakeven on a monthly basis, much faster compared to competition. So it is a byproduct of both the cost, faster breakeven time, our operation costs and the geography.
26:51 These are something which have given us success in the past and we are looking at replicating the same model going forward as well. Great. Thanks. And another small follow-up is like obviously, this has not been like enacted or anything, but there was also like some talk of like capping the new range and like taking it against like a three star hotel rate. So how do you look at like log in rates in comparison to like wherever you are operating? Some color on that would be helpful, yes. Those are topics which are still under discussion at statutory level. There are various healthcare representations also towards that because healthcare cannot be looked or compared from a hotel star category perspective.
27:40 Hospitals need to have their independent ranking system. That being said, our service delivery is in line with peers like Apollo Focus, Manipal or Swirely MRI. So our service delivery and our service offerings, including our environment, are in line with that, while our pricing compared to them might be at a 10% to 15% discount compared to location, depending on the location. Next question is from the line of Dharsh Mahida from JK Capital. Please go ahead. Hi, thanks for the opportunity. Just a couple of questions. Could you help us understand the key growth drivers during the quarter? So like how much of the growth was driven by improved occupancy or higher patient volumes?
28:30 And also should we expect this momentum to sustain in the second half of FY 'twenty seven? Sure. So we had almost 11% increase in the inpatient volumes at a network level, which obviously led to a higher throughput and increased occupancy levels. This was the primary reason for the growth. The Dhambraham, Havara, both these locations, was double digit growth, while locations like Salt Lake had around 10% growth. So these are primary factors which led to the overall increase in occupancy and thereby the revenue as well, along with obviously an incremental RBOB. That's great. And like could you share the occupancy trajectory you are targeting for each of the mature hospitals like over the next two quarters? In particular, what are the key initiatives being undertaken to improve utilization at Harvara and Agartala?
29:29 Sure. So Havra, have been focusing on higher end specialties. We have made significant progress with regards to orthopedics. We are doing almost more than 150 or 120 odd orthopedic procedures every month. We are now focusing on other allied specialties like cardiology and nephrology in that hospital as well, which should give a significant uptick in the overall occupancy levels. Salt Lake is already running at a good occupancy level of around 65 odd percent. We expect momentum to carry on Solar Lake is running at almost 68% occupancy with very limited scope of growth. We are working on our top numbers and optimizing the right metrics there. Ramdam is also working on almost 74% occupancy, which leaves very little room.
30:16 There also we are working on further optimizing our product mix. Aguirtaala is working at a 55% occupancy. As mentioned earlier, we have been focusing on high end specialties, especially around cardiology, oncology, nephrology there. These are continuous initiatives and investments we are taking in these departments, including addition of new consultants, which are starting to give us results. And we hope that we would be reaching an optimal occupancy around 70% in the near future. And just a last question, how is the oncology segment contributing to the hospital's overall revenue and ARPOV? Additionally, like with occupancy at 53.7 in Q2 FY 'twenty seven, so what is the future occupancy target? Are international patient inflows, particularly from Bangladesh, so it is showing a meaningful recovery?
31:06 So international patient flow is showing a slow recovery. It is not back as per the previous estimates or previous historical numbers. It is showing a slow recovery. But there is increased momentum. We are getting increased number of visa request letters. There have been change in processes in the overall international patient movement from Bangladesh. So but we are seeing increased requests coming in for sure. With regards to oncology, oncology is in association with our partners and we are seeing revenue contribution of around 4% at this point in the hospital, which is growing every quarter. We expect it to stabilize around 10% to 15% in the next four quarters. Perfect. Thank you so much and all the best. Thank you. Thank you.
31:55 Next question is from the line of Soumya Raghuvanci from Nirva Securities. Please go ahead. Good morning, sir. Thank you so much for the opportunity. So with Raipur reporting quarterly revenue of 9 crore in q two and occupancy improving to around 16.5 along with progress in key clinical milestones. Could you update us on whether the hospital remains on track to achieve the previously guided operational breakeven by Q3 FY 'twenty seven? As mentioned earlier, Raipur has some attrition in terms of clinical talent to newer competitions that come in. That is something which led to a slight dip in the overall productivity numbers in the second quarter, but we've made that good. We now have clinical talent back on board, and we expect the breakeven to be slightly delayed to quarter one of FY 'twenty eight.
32:53 All right. All right. Understood. So how are these high acuity procedures translating into incremental patient volumes and revenue? And what is the current specialty mix at Raipur? And how much of the hospital's revenue is now being generated from these advanced clinical services? So the Raipur Hospital is a quarterly care hospital where we are already doing complex procedures like liver transplant, renal transplant, EP studies and more. They have been good contributors to the overall revenue offerings at The good portion of the Raipur Hospital is that there is no dependence on anyone's specialty towards the revenues. All specialties from gastroenter Sciences to Cardiac Sciences, Renal Sciences have been contributing evenly across the spectrum. And a lot of it is coming from high end procedures.
33:47 We expect this momentum to continue basis to clinical pool which we have. And hopefully, as I said earlier, we should be breaking it by quarter one. Okay. All right. Just a last question from my end. As the facilities continues to scale, could you outline the key occupancy and revenue milestones required to achieve sustainable profitability? So we expect the Raipur Hospital to breakeven around the 35% occupancy mark. We are on track towards doing that. Others already are profitable and are delivering good results. It is only RIPOR, which is slightly below the expected profitability number. Next question is from the line of Jeeva, an individual investor.
34:39 Hello. Yes, good morning. Yes, go ahead. What's the current cash on the book, sir? Current cash is almost around INR45 crores standing in our mutual funds. And debt, sir, total borrowings? Borrowings are to the tune of around INR35 crores. Okay. Since our debt to equity is very low and we have scope for further leverage, is there any plan to increase the leverage, sir, under increasing We plan of will be obviously taking good healthy mix of debt and equity for our expansion. We will be taking some amount of debt for our Jamshedpur Hospital as well and the newer hospitals as and when the opportunities come in.
35:33 Next question is from the line of Nysar Shah from AMPL Asset Management. Please go ahead. Anurag, you think you can ever operate at 80% plus occupancies? It is very difficult for hospitals to operate at 80% plus occupancies. It requires a lot of downtime with regards to bed change. There are long stay patients. There are insurance approvals. Operating at 80% occupancy is a very big challenge, and very few hospitals are able to do it successfully. We have done it in the past before the restructuring of Ramdam. We hope to get to an optimal... We should be able to do... Get there, but beyond that is very difficult. So 80% you can get there? Okay. And Salt Lake and Dum Dum, where you already have a higher occupancy, is there a scope for reduction in ALOS there? And overall, what are your thoughts on network level ALOS?
36:33 So we have already optimized the network level ALOs, especially at the Dum Dum and Salt Lake Hospital. Salt Lake, the ALOs is around 2.9 to three. Even Dum Dum, the ALOs has gone down from almost 5.5 to just 4.3. So we have optimized the ALS to the best possible, levels considering the treatment standards and considering the kind of procedures we end up doing. Next question is from the line of Aditi Chedha from Incred Asset Management. How do we manage the doctor retention across the newer markets or tier two? You mentioned about removing clinical talent.
37:23 In your assessment, what is the, you know, right measures you would take in this... You know, also be, you know, relevant for the end of June 4? Sure. See, obviously, efforts are made to engage them properly and, you know, control. There are a lot of efforts put into engaging with them constantly so that there is a good synchronization between the doctors and the hospital team. We end up doing that. Unfortunately, there was a... There were competitive offerings in Raipur, which were not in sync with our estimates and not in sync with what we thought the market could offer. So there has been some amount of attrition there, but we do not expect that to happen in Jamshedpur. Jamshedpur, we know the market is much better from a product offering perspective and consultant retainability perspective as well. Plus, we have also slightly changed our strategy towards engaging with them at a much higher level. We have started organizing a lot of conferences recently at Agarta Lohspur. We organized a conference for the entire Northeast.
38:27 Similarly, are doing one in Raipur as well. So we are using a good mix of clinical and nonclinical initiatives to engage with the consultants. Got it. Thanks. Can you quantify the losses from Raipur and from Jamshedpur in FY 2028, if any ballpark range would also be helpful? So in FY 'twenty eight, we expect Raipur to be overall net positive just by a minor amount though. And Jamshedpur would have a loss of approximately 10 crores at an EBITDA level. And Raipur for FY 'twenty seven? Raipur for FY 'twenty seven, the loss should be to the tune of around INR 10 crores.
39:21 Next question is from the line of Anubhav Mukherjee from Crescent Capital. Please go ahead. Thanks for the follow-up opportunity. You hinted that increased competition led to some talent attrition at your IIT facility. So could you give some color on, like, has the competition increased compared to what you initially thought when you, like, chose the location? And also, I think Artemis also has set up a hospital in Raipur. So some color on how is the competition there would be very useful here. So we welcome any competition in these markets. This competition obviously help in improving the overall service offerings in that region. Yes, Artemis has entered into Raipur, but that led to some amount of attrition, but we've been able to make good that attrition again.
40:12 And we are also committed towards improving the overall productivity numbers and occupancy level at Raipur. That had a minor impact, but we are well past that now. Okay. And just a follow-up, like in terms of your focus on East And Central India. So also, what they are like given like slightly lower medical penetration compared to maybe other areas, like how are you seeing like, is there an increased focus on hospital teams in your like regions of focus? So definitely, with the potential Eastern India offers, there will be increased focus. But at the same time, we have been players in this region for quite some time.
40:58 We understand this region pretty well as well. So we feel we have a competitive advantage when it comes to our expansion opportunities. And at the same time, there is enough expansion opportunities for players to come in. Okay. Thanks. This was really helpful. Thank you. Thank you. Thank you, everyone, for joining us today. For any further queries, please contact Cygnus Partners Private Limited, the Investor Relations adviser to GPT Healthcare Limited. On behalf of GPT Healthcare Limited, we thank you for your participation. This concludes today's conference call. You may now disconnect your lines.
Follow GPT Healthcare Limited into a list and get an email when it puts out news.
executive director at GPT Healthcare Limited
at Electrum PMS
at Incred Asset Management
at Brookfield Estate
at Crescent Capital
at AMPL Asset Management
at Whitestone Financial Advisors
at JK Capital
at Nirva Securities
at AMPL Asset Management